Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

DB10800ApprovedInvestigationalVaccinesInactivated Meningococcal Vaccine

Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis serogroup W-135. The vaccine... The vaccine contains* N. meningitis* serogroup y capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae grown in another culture.

First approval
Canada, 2006 · United States, 2005
Also known as
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Brand names
  • Menactra

Resolves to

Clinical / RWD

What you can answer from here — as of January 07, 2026

26Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
4Marketed productsAcross 3 countries and 3 labellers
Sign in

Which other approved drugs treat the same conditions as Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account